MA47094A - Promédicaments d'ester aliphatique antiviral de ténofovir - Google Patents
Promédicaments d'ester aliphatique antiviral de ténofovirInfo
- Publication number
- MA47094A MA47094A MA047094A MA47094A MA47094A MA 47094 A MA47094 A MA 47094A MA 047094 A MA047094 A MA 047094A MA 47094 A MA47094 A MA 47094A MA 47094 A MA47094 A MA 47094A
- Authority
- MA
- Morocco
- Prior art keywords
- tenofovir
- antiviral
- aliphatic ester
- medicinal products
- ester medicinal
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229960004556 tenofovir Drugs 0.000 title 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437753P | 2016-12-22 | 2016-12-22 | |
| US201762574493P | 2017-10-19 | 2017-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47094A true MA47094A (fr) | 2021-05-26 |
Family
ID=60972454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047094A MA47094A (fr) | 2016-12-22 | 2017-12-20 | Promédicaments d'ester aliphatique antiviral de ténofovir |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10519159B2 (enExample) |
| EP (1) | EP3559011B1 (enExample) |
| JP (1) | JP6938637B2 (enExample) |
| KR (1) | KR20190100250A (enExample) |
| CN (1) | CN110099912B (enExample) |
| AU (1) | AU2017379850B2 (enExample) |
| BR (1) | BR112019013017A2 (enExample) |
| CA (1) | CA3047573A1 (enExample) |
| MA (1) | MA47094A (enExample) |
| MX (1) | MX388757B (enExample) |
| RU (1) | RU2759902C2 (enExample) |
| TW (1) | TW201829412A (enExample) |
| WO (1) | WO2018119013A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100108A1 (en) | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Antiviral phosphodiamide prodrugs of tenofovir |
| WO2017106069A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| WO2018039157A1 (en) * | 2016-08-25 | 2018-03-01 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| US10736908B2 (en) | 2016-10-26 | 2020-08-11 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
| KR20190100249A (ko) | 2016-12-22 | 2019-08-28 | 머크 샤프 앤드 돔 코포레이션 | 항바이러스 벤질-아민 포스포디아미드 화합물 |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| EP3730503B1 (en) * | 2017-12-21 | 2026-01-28 | Shenzhen TargetRx, Inc. | Antiviral nucleoside reverse transcriptase inhibitor |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| CN108586239B (zh) * | 2018-04-11 | 2020-12-29 | 深圳市前海博扬研究院有限公司 | 一种3-羟基丙酸甲酯的制备方法 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US11826375B2 (en) | 2018-07-19 | 2023-11-28 | Merck Sharp & Dohme Llc | Phosphinic amide prodrugs of tenofovir |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| HRP20240541T1 (hr) | 2018-10-31 | 2024-07-05 | Gilead Sciences, Inc. | Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1 |
| JP7503558B2 (ja) | 2019-01-25 | 2024-06-20 | ブラウン ユニバーシティ | 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法 |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| KR102054104B1 (ko) * | 2019-04-30 | 2019-12-09 | 유니셀랩 주식회사 | 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| KR102776925B1 (ko) | 2019-06-25 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| FI4037708T3 (fi) | 2019-09-30 | 2024-10-31 | Gilead Sciences Inc | Hbv-rokotteita ja menetelmiä, hbv:n hoitamiseksi |
| EP4567109A3 (en) | 2019-12-06 | 2025-09-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN111018916B (zh) * | 2019-12-30 | 2022-04-29 | 天津天士力圣特制药有限公司 | 一种替诺福韦苯基烷基酯膦酰胺前体的合成方法 |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| EP4192474B1 (en) * | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| WO2022066882A1 (en) * | 2020-09-23 | 2022-03-31 | Oncolinea Pharmaceuticals, Inc. | Method for treating cancer with a reverse transcriptase inhibitor |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合 |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US11999733B2 (en) | 2021-06-23 | 2024-06-04 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| OA12393A (en) | 2000-07-21 | 2006-04-18 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same. |
| PL2204374T3 (pl) | 2003-12-30 | 2012-11-30 | Gilead Sciences Inc | Fosfoniany nukleozydów i ich analogi do leczenia zakażeń HPV |
| WO2006114064A2 (en) | 2005-04-25 | 2006-11-02 | Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic | Use of compounds to enhance processivity of telomerase |
| WO2007002912A2 (en) | 2005-06-29 | 2007-01-04 | Gilead Sciences, Inc. | Anti-proliferative compounds, compositions, and methods of use thereof |
| AU2007269557B2 (en) | 2006-07-07 | 2013-11-07 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| US9156874B2 (en) * | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| CN103403014B (zh) | 2011-01-03 | 2016-07-06 | 河南美泰宝生物制药有限公司 | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 |
| CN102887901B (zh) | 2011-07-01 | 2015-01-07 | 四川好医生攀西药业有限责任公司 | 无环核苷酸类似物及其制备方法和应用 |
| JP5651275B2 (ja) | 2011-08-16 | 2015-01-07 | ギリアード サイエンシス インコーポレーテッド | テノホビルアラフェナミドヘミフマレート |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| CN103435672A (zh) * | 2013-04-25 | 2013-12-11 | 刘沛 | 含有取代苄基的新型核苷磷酸酯前药的结构与合成 |
| WO2015197006A1 (zh) * | 2014-06-25 | 2015-12-30 | 四川海思科制药有限公司 | 一种取代的氨基酸硫酯类化合物、其组合物及应用 |
| CN112898345A (zh) | 2014-09-15 | 2021-06-04 | 加利福尼亚大学董事会 | 核苷酸类似物 |
| CN106188139B (zh) * | 2015-05-29 | 2020-02-18 | 江苏天士力帝益药业有限公司 | 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用 |
| WO2017007701A1 (en) | 2015-07-07 | 2017-01-12 | Merck Sharp & Dohme Corp. | Antiviral phosphodiamide compounds |
| EP3334743B1 (en) | 2015-08-10 | 2023-11-29 | Merck Sharp & Dohme LLC | Antiviral beta-amino acid ester phosphodiamide compounds |
| US10377782B2 (en) | 2015-09-15 | 2019-08-13 | The Regents Of The University Of California | Nucleotide analogs |
| CN106167504A (zh) | 2015-11-04 | 2016-11-30 | 洛阳聚慧医药科技有限公司 | 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用 |
| RU2604068C1 (ru) * | 2015-12-10 | 2016-12-10 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук | N-(2-аминопурин-6-ил)глицил-(s)-глутаминовая кислота, обладающая противотуберкулёзной активностью |
| WO2017100108A1 (en) | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Antiviral phosphodiamide prodrugs of tenofovir |
| WO2017106069A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| WO2018039157A1 (en) * | 2016-08-25 | 2018-03-01 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
| US10736908B2 (en) | 2016-10-26 | 2020-08-11 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
| KR20190100249A (ko) | 2016-12-22 | 2019-08-28 | 머크 샤프 앤드 돔 코포레이션 | 항바이러스 벤질-아민 포스포디아미드 화합물 |
-
2017
- 2017-12-20 WO PCT/US2017/067470 patent/WO2018119013A1/en not_active Ceased
- 2017-12-20 JP JP2019533490A patent/JP6938637B2/ja not_active Expired - Fee Related
- 2017-12-20 CA CA3047573A patent/CA3047573A1/en not_active Abandoned
- 2017-12-20 MA MA047094A patent/MA47094A/fr unknown
- 2017-12-20 AU AU2017379850A patent/AU2017379850B2/en not_active Ceased
- 2017-12-20 CN CN201780079454.4A patent/CN110099912B/zh not_active Expired - Fee Related
- 2017-12-20 MX MX2019007585A patent/MX388757B/es unknown
- 2017-12-20 BR BR112019013017A patent/BR112019013017A2/pt active Search and Examination
- 2017-12-20 RU RU2019122414A patent/RU2759902C2/ru active
- 2017-12-20 US US15/847,971 patent/US10519159B2/en active Active
- 2017-12-20 EP EP17829499.7A patent/EP3559011B1/en active Active
- 2017-12-20 KR KR1020197020682A patent/KR20190100250A/ko not_active Withdrawn
- 2017-12-20 TW TW106144739A patent/TW201829412A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017379850A1 (en) | 2019-06-13 |
| WO2018119013A1 (en) | 2018-06-28 |
| CN110099912A (zh) | 2019-08-06 |
| US10519159B2 (en) | 2019-12-31 |
| RU2759902C2 (ru) | 2021-11-18 |
| US20180179208A1 (en) | 2018-06-28 |
| JP2020504733A (ja) | 2020-02-13 |
| RU2019122414A (ru) | 2021-01-25 |
| EP3559011A1 (en) | 2019-10-30 |
| KR20190100250A (ko) | 2019-08-28 |
| BR112019013017A2 (pt) | 2020-01-14 |
| AU2017379850B2 (en) | 2022-03-24 |
| MX2019007585A (es) | 2019-09-09 |
| EP3559011B1 (en) | 2022-04-13 |
| MX388757B (es) | 2025-03-20 |
| CN110099912B (zh) | 2021-10-15 |
| JP6938637B2 (ja) | 2021-09-22 |
| RU2019122414A3 (enExample) | 2021-04-26 |
| TW201829412A (zh) | 2018-08-16 |
| CA3047573A1 (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47094A (fr) | Promédicaments d'ester aliphatique antiviral de ténofovir | |
| PT3607939T (pt) | Formulações farmacêuticas compreendendo tenofovir e emtricitabina | |
| ZA201903101B (en) | Pharmaceutical formulations | |
| EP3503895A4 (en) | ANTIVIRAL PRODRUGS BY TENOFOVIR | |
| HUE046850T2 (hu) | Új 2' és/vagy 5' aminosav észter foszforamidát 3'-deoxi adenozin származékok mint anti-rák vegyületek | |
| EP3337396A4 (en) | SYNCHRONIZED PULSE DETECTOR | |
| PT3426294T (pt) | Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina | |
| EP3525841A4 (en) | MICRO DELIVERY DEVICE | |
| IL266537A (en) | pharmaceutical preparation | |
| MA44987A (fr) | Formulations de médicaments améliorées | |
| EP3638230A4 (en) | Antiviral drugs | |
| EP3383397A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH DORAVIRIN, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDIN | |
| MA46642A (fr) | Promédicaments d'inhibiteurs de la kallicréine | |
| EP3302477A4 (en) | PHARMACEUTICAL FORMULATIONS FOR THE DELAYED RELEASE OF SEBACOYLDINALBUPHINESTER | |
| ZA201807851B (en) | Pharmaceutical formulation | |
| EP3395363A4 (en) | ANTIVIRAL MEDICINAL PRODUCT | |
| IL271908A (en) | Over-compressed pharmaceutical preparations | |
| IL255635A (en) | Antiviral pharmaceutical composition for topical use | |
| ES1141665Y (es) | Dispositivo para la administración de un producto cosmético | |
| HUE057830T2 (hu) | Famitinib tartalmú gyógyszerkészítmény | |
| HUP1600415A2 (en) | Pimavanserin salts for the manufacture of pharmaceutical formulations | |
| UA35313S (uk) | Сувенірний виріб «бандура» | |
| UA35311S (uk) | Сувенірний виріб «бандура» | |
| UA34521S (uk) | Упаковка для лікарського засобу «урофосцин» | |
| UA37338S (uk) | Розгортка упаковки лікарського засобу |